METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS
申请人:ELAN PHARMACEUTICALS, INC.
公开号:EP1734961A2
公开(公告)日:2006-12-27
[EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS<br/>[FR] PROCEDES DE TRAITEMENT DE L'AMYLOSE METTANT EN OEUVRE DES INHIBITEURS DE LA PROTEASE A BASE D'ASPARTYLE BICYCLIQUE
申请人:ELAN PHARM INC
公开号:WO2005087714A2
公开(公告)日:2005-09-22
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
Keto−Enol/Enolate Equilibria in the Isochroman-4-one System. Effect of a β-Oxygen Substituent
作者:Y. Chiang、A. J. Kresge、Q. Meng、R. A. More O'Ferrall、Y. Zhu
DOI:10.1021/ja0112801
日期:2001.11.1
for isochroman-4-one gave the keto-enolequilibriumconstant pK(E) = 5.26, the acidity constant of the enol ionizing as an oxygen acid p = 10.14, and the acidity constant of the ketone ionizing as a carbon acid p = 15.40. Comparison of these results with those for 1-tetralone shows that the beta-oxygen substituent in isochroman-4-one raises all three of these constants: K(E) by 2 orders of magnitude